ZURICH (Reuters) - Swiss drugmaker Roche said on Wednesday a late-stage study of its treatment for slow-growing, or indolent, non-Hodgkin's lymphoma showed significant benefit and met its primary endpoint early.
via Reuters: Health News Read More Here..
No comments:
Post a Comment